Scarica l'app Stockscreener
1.29
2.27%
-0.03
Dopo l'orario di chiusura:
1.30
0.01
+0.78%
Precedente Chiudi:
$1.32
Aprire:
$1.28
Volume 24 ore:
42,745
Relative Volume:
0.65
Capitalizzazione di mercato:
$5.19M
Reddito:
-
Utile/perdita netta:
$-7.10M
Rapporto P/E:
-0.2431
EPS:
-5.3059
Flusso di cassa netto:
$-8.30M
1 W Prestazione:
+1.57%
1M Prestazione:
+0.00%
6M Prestazione:
-50.00%
1 anno Prestazione:
-81.55%
Intervallo 1D:
$1.275
$1.3964
Intervallo di 1 settimana:
$1.20
$1.3964
Portata 52W:
$1.10
$7.33
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Nome
Dermata Therapeutics Inc
Settore
Industria
Telefono
(858)-223-0882
Indirizzo
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.29 | 5.31M | 0 | -7.10M | -8.30M | -5.3059 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Dermata Therapeutics Inc Borsa (DRMA) Ultime notizie
Dermata Therapeutics Inc (DRMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
DRMA|Dermata Therapeutics Inc|Price:1.290|Chg%:-0.030 - TradingKey
Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dermata Therapeutics, Inc. Revenue Breakdown – BOATS:DRMA - TradingView
TradingKey - TradingKey
Dermata Therapeutics, Inc. Revenue Breakdown – BOATS:DRMAW - TradingView
Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Price to sales forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Enterprise value to revenue forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Price to book forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
DRMA Q1 2026 Earnings: EPS Surprise of 11.21% Beats Estimates Amid No Revenue GenerationDividend Earnings Report - dars.gov.et
Dermata Therapeutics Inc Warrant 2021- on Dermata Therapeutics Financial Disclosures & SEC Filings - TradingView
Dermata Therapeutics Warrant (DRMAW) Holds at $0.01 – Warrants Remain at Key Support LevelCombination Correction - dars.gov.et
Price to earnings forward of Dermata Therapeutics, Inc. – BOATS:DRMAW - TradingView
Dermata Therapeutics, Inc. Actuals & Estimates (NASDAQ:DRMA) - TradingView
Enterprise value to EBIT forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA - TradingView
DRMA Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA - TradingView
Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMA - TradingView
Dermata Therapeutics Inc (DRMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dermata Therapeutics Inc (DRMAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lixte Biotechnology Holdings, Inc. (LIXTW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dermata Therapeutics Inc (DRMA) Institutional Confidence - TradingKey
Dermata Therapeutics Inc (DRMAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dermata Therapeutics Inc (DRMAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dermata Therapeutics Inc (DRMAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dermata Therapeutics Inc (DRMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dermata Therapeutics Inc (DRMAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dermata Therapeutics Inc (DRMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dermata Therapeutics Inc (DRMAW) Institutional Confidence - TradingKey
Dermata Therapeutics Inc (DRMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dermata Therapeutics Inc (DRMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dermata Therapeutics Inc - TradingKey
Dermata Therapeutics Inc (DRMAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dermata Therapeutics Inc (DRMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dermata Therapeutics (NASDAQ: DRMA) director reports small open-market stock sale - Stock Titan
Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment - timothysykes.com
Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch - timothysykes.com
Dermata Therapeutics Q1 2026 Earnings: EPS Surprise Beats Estimates Amid Pre-Revenue Biotech OperationsPost-Earnings Drift - dars.gov.et
Dermata Therapeutics Warrant (DRMAW) Slides 19.73% as Price Nears Critical Floor at $0.01Dark Pool Volume - newsline.com
DRMA Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Control Amid Pipeline ProgressQuarterly Financial Update - newsline.com
DRMA Q1 2026 Earnings: Better-than-Expected Loss Reduction Amidst Pipeline Development FocusShare Dilution Risk - newsline.com
DRMA Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Advances ContinueSlow Growth Warning - newsline.com
Dermata Therapeutics (DRMA) Edges Higher as Stock Tests Key Resistance LevelsVolume Climax - newsline.com
DRMA Q1 2026 Earnings: Positive EPS Surprise as Dermata Advances PipelinePreliminary Results - newsline.com
CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D - Stock Titan
[EFFECT] Dermata Therapeutics, Inc. SEC Filing - Stock Titan
Dermata Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Dermata Therapeutics Warrant (DRMAW) Holds at Penny Level – Key Levels to WatchPoint of Control - newsline.com
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf registration - Stock Titan
Dermata Therapeutics (DRMA) Stages Modest Recovery – Support Holds Above $1.28Keltner Channel - The Legal Advocate
Dermata Therapeutics Inc Azioni (DRMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):